| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 726.86 | 11.3% | 13.2% |
| Total Income | 774.19 | 10.9% | 13.2% |
| Expenditure | 483.42 | 14.7% | 12.7% |
| PBT | 422.83 | 52.8% | 65.6% |
| Net Profit | 313.25 | 53.2% | 65.7% |
| OPM | 54.10% | 16.20pp | 18.30pp |
| NPM | 40.46% | 11.17pp | 12.83pp |
| EPS | 68.47 | 53.2% | 65.7% |
Detailed report is being prepared.
Mid-cycle momentum on track, but Minipress discontinuation casts shadow
Q2 expectations: ~₹706 Cr revenue, 8% growth on-plan. Street holds strong buy at ₹6,659 target. Watch: Minipress XL impact quantified, margin hold amid divisional headwinds.
The setup
Pfizer Ltd enters Q2 FY27 on mid-cycle momentum. Q1 posted ₹653.17 Cr revenue (+8.3% YoY) and ₹204.47 Cr net profit (+6.6% YoY), tracking in line with FY27 consensus guidance of ₹2.73k Cr revenue (+8.2% growth) and ₹176.70 EPS (+4.8% growth). The Street—bulked on analyst consensus of Strong Buy at ₹6,659 (S&P Global, 4 analysts)—sees the company repricing upward from current ₹3,709.8 (down -42% from ATH ₹6,451, but +3.3% off the 52-week low). The debate: can core growth sustain after the Minipress XL product exit, and how will margin dynamics play under leadership transition?
~₹706 Cr
8% YoY growth on-plan; Q1 grew 8.3%, run-rate sustained
~₹218 Cr
6–7% growth; margin hold assumed absent one-time items
₹176.70 FY27
FY27 consensus +4.8% YoY; pace requires sustained mid-singles growth
₹6,659
S&P 4-analyst consensus; stock at -44% discount to target
A strong print would show
Core revenue growth of 9–10% (above Q1's 8.3%), margin expansion from operational leverage, and clear quantification of Minipress XL's contribution to prior quarters' topline and the net impact of the $13.9M received. A beat on profit—₹220+ Cr—would signal cost discipline and set up confidence for H2 guidance despite executive turnover.
A weak print would show sub-8% revenue growth (momentum loss) or margin compression below prior-quarter levels, coupled with vague disclosure of Minipress discontinuation impact or guidance withdrawal for H2 FY27.
Is the company on track?
Yes—on the numbers. Q1 FY27 revenue +8.3%, profit +6.6% paces toward FY27 consensus of +8.2% and +4.8% respectively. The issue is visibility. Minipress XL, a marketed product, exits Sep 7 following parent (Pfizer Inc. USA) discontinuation. The company disclosed receipt of $13.9M (~ ₹116 Cr at September rates) but has not broken out Minipress's annualized topline contribution or the P&L impact post-exit. That clarity is essential for FY27 re-baselining and H2 guidance.
Since last quarter
1 · Minipress XL discontinuation (Sep 7, 2026)
Business impact: Pfizer India halted marketing, distribution, and sale of Minipress XL following parent's manufacturing discontinuation. Received $13.9M from Pfizer Inc. USA, but the company has not disclosed the historical contribution (₹ Cr p.a.) of this product or bridge assumptions for remaining FY27 guidance. This is the largest visible product exit in recent results.
2 · CFO resignation & leadership transition (Jul 27, Oct 8, 2026)
Amit Agarwal (Executive Director – Finance & CFO) resigned effective Oct 8, 2026, to pursue external opportunity. No successor named as of Oct 27 reporting. This leaves the company without a permanent CFO at a key moment (pre-result, post-product exit). Watch for interim leadership announcement and any guidance walk-back on Nov 3 call.
3 · Transfer Pricing audit penalty (Sep 29, 2026)
Income Tax Department levied ₹1.26 Cr penalty (AY 2023-24) for Transfer Pricing audit findings. Routine compliance matter, but flagged for tax exposure in a company with global parent relationships. Likely a one-time charge; watch for reserve/disclosure in Q2 P&L.
4 · Senior Director – Policy exit (Sep 18, 2026)
Sharad Goswami (Senior Director – Policy & Public Affairs) resigned effective Sep 25 to pursue external opportunity. Routine departure, but combined with CFO exit, signals management churn. Regulatory/policy continuity watch going into Q3–Q4 (key for pharma licensing, approvals).
5 · Ownership flows (FY27 Q1 vs. FY26 Q2)
FII outflow: FII holdings down 116 bps (2.81% → 1.65%) between Jun 2026 and Sep 2026. DII inflow: DII up 91 bps (16.89% → 17.80%). Promoter flat at 63.92%. The FII selling into the weakness (stock -42% from ATH) may reflect valuation concerns or dividend yield compression vs. global pharma.
What to watch on result day (Nov 3)
The headline: Q2 revenue & profit growth rates (expect ₹706 Cr, +8% YoY). The key disclosure: Minipress XL historical contribution and bridge to FY27E guidance—failure to quantify will spook Street. The tone: CFO's parting commentary on divisional momentum, margin drivers, and H2 expectations. The signal: Any guidance cut or withdrawal flags deeper structural headwinds. The call vibe: Interim CEO/CFO + new faces—watch for confident re-iteration or defensive posture.
Pfizer Ltd Q2 enters on mid-cycle momentum: Q1 revenue +8.3%, profit +6.6%, tracking FY27 Street consensus of +8.2% and +4.8% growth. At ₹3,709.8, the stock trades -44% below consensus targets (₹6,659), suggesting the market is pricing in slowdown or downside risk. The Minipress XL exit (Sep 7, $13.9M received, but P&L bridge not yet disclosed) and CFO transition (effective Oct 8, no successor named) are the wildcards. A strong print means 8%+ revenue growth, margin hold, and clear disclosure of Minipress impact with reaffirmed H2 guidance. A weak print: sub-8% growth or margin slip, paired with fuzzy disclosures or guidance withdrawal. Street remains Strong Buy (4 analysts, ₹6,659 target), but thin coverage and recent leadership churn mean execution clarity is priced in.
Revenue from operations
₹653.17 Cr+8.3% YoY
~₹706 Cr
sustained 8% growth; Minipress headwind assumed offset by core portfolio
Net profit
₹204.47 Cr+6.6% YoY
~₹218 Cr
6–7% growth; TP penalty (₹1.26 Cr) likely one-time, margin stable
EPS
~₹38.70+6.6% (est.)
~₹41.50
tracking ₹176.70 FY27E (+4.8% annual)
Dividend yield (est.)
—~1.8–2.0% fwd
FY26 ₹75; Street yield compression vs. FY25